| . | Quality assessment . | Summary of findings . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Directness . | No of events . | . | ||
| No. of studies (ref.) . | Design . | Limitations . | Consistency . | Generalizability to population of interest . | Generalizability to intervention of interest . | Intervention . | Control . | Relative benefita(95% CI) . |
| Measles Mortality: moderate outcome specific quality | ||||||||
| 5 (46–51) | RCT | None | No heterogeneity | Only African studies (−0.5) | Different doses of vitamin A (−0.5) | 19 | 33 | 37% (−8 to 63)b |
| Measles mortality (At least two doses of 200 000 IU for children and 100 000 IU for infants): moderate outcome specific quality | ||||||||
| 3 (46–48) | RCT | <50 events (−0.5)c | No heterogeneity | Only African studies (−0.5) | Generalizable | 8 | 23 | 62% (19 to 82)b |
| . | Quality assessment . | Summary of findings . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Directness . | No of events . | . | ||
| No. of studies (ref.) . | Design . | Limitations . | Consistency . | Generalizability to population of interest . | Generalizability to intervention of interest . | Intervention . | Control . | Relative benefita(95% CI) . |
| Measles Mortality: moderate outcome specific quality | ||||||||
| 5 (46–51) | RCT | None | No heterogeneity | Only African studies (−0.5) | Different doses of vitamin A (−0.5) | 19 | 33 | 37% (−8 to 63)b |
| Measles mortality (At least two doses of 200 000 IU for children and 100 000 IU for infants): moderate outcome specific quality | ||||||||
| 3 (46–48) | RCT | <50 events (−0.5)c | No heterogeneity | Only African studies (−0.5) | Generalizable | 8 | 23 | 62% (19 to 82)b |
NC, not calculated.
aRelative benefit is 1 – RR.
bCalculated with Mantel–Haenszel method
cDeduction to account for Rule 0 of CHERG Rules for Evidence Review.
| . | Quality assessment . | Summary of findings . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Directness . | No of events . | . | ||
| No. of studies (ref.) . | Design . | Limitations . | Consistency . | Generalizability to population of interest . | Generalizability to intervention of interest . | Intervention . | Control . | Relative benefita(95% CI) . |
| Measles Mortality: moderate outcome specific quality | ||||||||
| 5 (46–51) | RCT | None | No heterogeneity | Only African studies (−0.5) | Different doses of vitamin A (−0.5) | 19 | 33 | 37% (−8 to 63)b |
| Measles mortality (At least two doses of 200 000 IU for children and 100 000 IU for infants): moderate outcome specific quality | ||||||||
| 3 (46–48) | RCT | <50 events (−0.5)c | No heterogeneity | Only African studies (−0.5) | Generalizable | 8 | 23 | 62% (19 to 82)b |
| . | Quality assessment . | Summary of findings . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Directness . | No of events . | . | ||
| No. of studies (ref.) . | Design . | Limitations . | Consistency . | Generalizability to population of interest . | Generalizability to intervention of interest . | Intervention . | Control . | Relative benefita(95% CI) . |
| Measles Mortality: moderate outcome specific quality | ||||||||
| 5 (46–51) | RCT | None | No heterogeneity | Only African studies (−0.5) | Different doses of vitamin A (−0.5) | 19 | 33 | 37% (−8 to 63)b |
| Measles mortality (At least two doses of 200 000 IU for children and 100 000 IU for infants): moderate outcome specific quality | ||||||||
| 3 (46–48) | RCT | <50 events (−0.5)c | No heterogeneity | Only African studies (−0.5) | Generalizable | 8 | 23 | 62% (19 to 82)b |
NC, not calculated.
aRelative benefit is 1 – RR.
bCalculated with Mantel–Haenszel method
cDeduction to account for Rule 0 of CHERG Rules for Evidence Review.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
